Company Description
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications.
It also provides BioXp Select kits which offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications such as cloning, mRNA generation from plasmid and cell free amplification; BioXp Next Generation Sequencing kits which contains the necessary reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents necessary to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom gibson short oligo ligation assembly enzymatic DNA synthesis solutions, designed reduce timelines for constructing synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines.
The company serves its products to government institutions, contract research organizations, and synthetic biology companies.
The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022.
Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 18, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Dr. Todd R. Nelson MBA, Ph.D. |
Contact Details
Address: 10431 Wateridge Circle, Suite 150 San Diego, California 92121 United States | |
| Phone | 858-228-4115 |
| Website | codexdna.com |
Stock Details
| Ticker Symbol | TBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001850079 |
| CUSIP Number | 89374L104 |
| ISIN Number | US1920031010 |
| Employer ID | 45-1216839 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd R. Nelson MBA, Ph.D. | Founder, Chief Executive Officer and Director |
| Daniel G. Gibson Ph.D. | Chief Technology Officer |
| Robert H. Cutler | Chief Legal Officer |
| Eric Esser | President and Chief Operating Officer |
| William J. Kullback | Chief Financial Officer |
| Jen Carroll | Vice President of Investor Relations |
| Decky Goodrich M.B.A. | Senior Vice President of Corporate Development |
| Laura B. Puga M.B.A. | Vice President of People and Culture |
| Laurence Warden | Senior Vice President of Engineering and Instrumentation |
| Richard Lepke | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 9, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 3, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Nov 30, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |